Taxus Cardium Pharmaceuticals Group Inc (CE) News - CRXM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

FeaturedNorthstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Form REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]

Amended Annual Report (10-k/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Ame...

Annual Report (10-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ...

Quarterly Report (10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Amended Current Report Filing (8-k/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Annual Report (10-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...

Statement of Beneficial Ownership (sc 13d)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Gnarlyman 1 month ago

Seems dumb for an investor research firm to include a defunct company in this report.
https://www.einpresswire.com/article/778637651/gene-therapy-market-size-is-expected-to-reach-usd-29-24-billion-by-2033-growing-at-a-cagr-of-18-60-straits-research

👍 2

bentleyt 1 month ago

Altitrade As Far As You Folks See Is CRXM Having Any Success Funding The Generx Phase 3 ?.....Absolutely Zero Updates To Shareholders From The Company

👍️ 2

crazyflavor 2 months ago

Here is what your likely to hear if you want to file a lawsuit:

-What is the basis for your complaint / lawsuit?
-What are your damages?
-How are you going to prove that laws were broken?
-Is this a class action lawsuit?
-What attorney / law firm with experience to do so is going to take this case?
-Are you suing Nostrum, CRXM (bc CRXM seems pretty judgement proof) or both?

*Attorneys are expensive, I can't imagine one taking this on spec and you'd probably spend more trying to get back what you lost. I've been in litigation 2x and both of those have taken well over a yr to resolve. Courts don't move quickly.

👍️0

bentleyt 2 months ago

October 30 2023....Nostrum and its founder and CEO Nirmal Mulye settled with the DOJ for underpaying Medicaid rebates....They are fined and have agreed to pay anywhere from $3,825,000 to $50,000,000.....This hurt CRXM shareholders as they have basically abandoned the company.....The company never filed their financials in a timely fashion and the stock is currently delisted with zero value....IMHO Shareholders should consider legal recourse if things don't turn around in a reasonable timely fashion

👍️ 4 💯 3

campe 2 months ago

Nostrum needs to let go the reigns and let the market blow some life back into this thing, before anyone catches up and leaves their CRXM tech in the dust.

👍️ 1

bentleyt 2 months ago

JJ24....Whats Up....I Sent You A Private Message

👍️ 1

docj 3 months ago

My understanding and I may be misinformed, the offer was arounf $10 million. Why would Nostrum turn down such a sum given the situation they are/were in?

There is a potential asset woth minimally hunfreds of millions to Nostrum/CRXM and between the 2 companies they can't make a deal for one or the other to be purchased outright or raise $20-25 million to get to the finish line within a year or two?

Something isn't right with this picture.

👍 1

Altitrade Partners 3 months ago

It wasn't significant enough, I guess.

👍 1

docj 3 months ago

Didn't CRXM try to buy Nostrum out fairly recently and Nostrum turned down a significant amount of money?

👍 1

Altitrade Partners 3 months ago

Nostrum would need to buy into that idea and I'm not sure they would.

👍 1

campe 3 months ago

If he can't raise the $$, why not just sell to a larger pharma? At least his research would move forward and not die on the wine.

It must be worth something to someone...

👍 1

Altitrade Partners 3 months ago

Nothing has changed, and the stock will likely never trade again. The future of the GeneRx clinical trial can only be secured if Chris Reinhard raises the capital required (approximately $25 million) to fund the next step to move to a Phase 3 trial. The results from the clinical trial will determine what happens from there. I have chosen not to write this off as a tax deduction since there is still a glimmer of hope, albeit a very small one.

👍 1

docj 3 months ago

Altitrade Partners:

The below post was from a few months ago. Has your thinking changed any as time has passed and we are at years end? I personally have one of my family members wondering if they should take a tax loss at this point on their CRXM position.

Altitrade Partners

Re: bentleyt post# 6166

Friday, September 06, 2024 9:40:40 AM

Post#
6167
of 6188
It depends on three things:

1. They can obtain funding for a Phase 3 clinical trial of GeneRx.
2. They get a favorable outcome and FDA approval of the drug.
3. They can attract a Big Pharma company to purchase the drug.

I doubt that this company's shares will ever trade again. Instead, CRXM will likely implement an exit strategy for its shareholders based on the above, where the shareholders receive a portion of the proceeds based on any sale of GeneRx.

As I have often said, shareholders should view this as an investment in a private company.
"All truth passes through three stages. First, it is ridiculed. Second, it is violently opposed. Third, it is accepted as being self-evident." ~ Arthur Schopenhauer

👍 1

bentleyt 3 months ago

docj.....Yes It Would Be Nice If The Company Would Provide Some Kind Of Update....Complete Disregard Of Shareholders.....Regardless Also Wishing Everyone A Happy And Healthy Holiday Season

👍 2

docj 3 months ago

Anything on the funding?

I wish everyone a great holiday and Happy New Year!

👍 1

docj 4 months ago

I was told to expect CR to respond to the SEC. Apparently he did not.

I'm not sure if CRXM even exists as a company at this point.

I am extremely disappointed in the CRXM management team for not communicating an update with shareholders.

👍 2

docj 4 months ago

https://www.sec.gov/files/litigation/opinions/2024/34-101312.pdf

👍️0

Gnarlyman 4 months ago

When did CRXM disappear from OTC, anyone else unable to search the ticker?

👍️0

docj 4 months ago

I’m giving up my moderator position here on the CRXM board. Anyone interested in jumping in is welcome to do so.

Best to you all.

👍️ 1

benyam 4 months ago

why they updare website it s donw ????

👍️0

benyam 4 months ago

i m mostly ao sad trial was allmost done shareholder loose and people loose amazing that no financong or whatever

👍️0

docj 5 months ago

Does anyone know if a new entity has been formed and if our CRXM common shares affords us an ownership interest is this new entity?

👍️ 1 🙏 2

docj 5 months ago

OTC Markets didn't find anything for CRXM when I checked. Given the SEC's latest letter to Gene Bio, can't say I am surprised. I will say I'm disappointed in CR at the moment. The least he could do is put a banner on the company website providing some clarity on where things stand. Chris, do the right thing and give shareholders an update!

👍️ 1

bentleyt 5 months ago

See Altitrade post 9/6/24.....They believe we have shares in what will become a private company.....Hopefully they raise the $ for the Phase 3 Generx Trial

👍️ 1 😉 1

benyam 5 months ago

yeah but crxm have been delister so our story is over

👍️0

bentleyt 5 months ago

The CEO picked bad partners with Nostrum.....Now trying to raise $20,000,000 for Phase 3 Generx trial....How about getting a real deal Biotech involved.....CRXM has to get Nostrum out of the picture!

👍️ 1

benyam 5 months ago

difficult to understand that crxm saga didn t continue to last trial

👍️0

benyam 5 months ago

so we are delisted now

👍️0

Renee 5 months ago

CRXM SEC registration revoked:

https://www.sec.gov/files/litigation/opinions/2024/34-101312.pdf

👍️0

docj 5 months ago

Any information on how much success there has been raising money for the trial?

I’m not sure about trading again. It will require a huge investment to get current. Unless CR has come up with another project to pursue that being a public traded company would be of benefit. Or another indication for Generx that gets carved out from the hoped for trial and new investors.

👍️0

JJ24 5 months ago

Spoken to Rinehardt a few times over the last few months . He always says he’s working on it . If we trade again it will sky rocket .

👍️ 3 🙏 1

benyam 5 months ago

tick tock bit when boom it s big question if never

👍️0

bentleyt 6 months ago

Altitrade....Appreciate your take on the situation....We have to hope for the best

👍️ 1

benyam 6 months ago

only i ll can tell it s amazing that they don t have get money injection from some big pharma

👍️0

Altitrade Partners 6 months ago

It depends on three things:

1. They can obtain funding for a Phase 3 clinical trial of GeneRx.
2. They get a favorable outcome and FDA approval of the drug.
3. They can attract a Big Pharma company to purchase the drug.

I doubt that this company's shares will ever trade again. Instead, CRXM will likely implement an exit strategy for its shareholders based on the above, where the shareholders receive a portion of the proceeds based on any sale of GeneRx.

As I have often said, shareholders should view this as an investment in a private company.

👍️ 1

bentleyt 6 months ago

Altitrade....What Do You Think Of The Future Of This Company ???

Any unofficial updates regarding CRXM?

👍️0

benyam 7 months ago

it s amazing that cannpt get financing to phase 3 soo big market possibilities

👍️0

docj 7 months ago

I understand CYDY has used AI to come up with additional formulas and indications for leronlimab. Unfortunately I don't think Chris has the money to do anything like that although it could present some options.

3 months or more since I have been aware of the $20m plan. Be nice to hear an update.

👍️ 1

bentleyt 7 months ago

Right now Chris should use AI and come up with a list of strong pharmaceutical companies and investors.....The $20,000,000 could be raised easily....Lets replace Nostrum with some good people!

👍️ 2

JJ24 7 months ago

Every conversation I have had with Chris which he can’t say much but I believe he’s doing everything he can to get phase 3 going . We were so close to having phase 3 started with FUJIFILM Diosynth Biotechnologies. If Nostrum didn’t get hammered by the DOJ for up to $50 million we would have been in phase 3 . If Chris gets us trading again and in phase 3 I will retire early from this play . If not I am on Track to working till i am in my grave .

👍️ 4

benyam 7 months ago

crxm website are active anyways

👍️0

docj 8 months ago

If the company stays private, there needs to be a way to connect shareholders to buy and sell shares. I owned a shares of stock in a local community bank that was growing its business. The President of the bank had a list of buyers and sellers he would connect. Eventually a link on the banks website allowed shareholders to deal directly with each other.

👍️ 1

docj 8 months ago

It would be nice to hear progress details. I'm keeping my fingers crossed CR will be able to put the financing together to move forward with the study. It will be interesting to hear what is in store for CRXM as a company and common shareholders.

👍️ 1

JJ24 8 months ago

I got this feeling we hear something soon .

👍️ 2

docj 8 months ago

Hey, BTW, I just saw your private reply post to me from back in May.

I do have the document but I won't share more since I did the super secret handshake. LOL. Perhaps CR will make it available soon.

👍️0

crazyflavor 8 months ago

Do you have a link to the pp? I don’t see it anywhere

👍️0

BlueChip$ 8 months ago

So you're saying there's a chance!...YES!

👍️0

campe 8 months ago

Thanks for posting. Good to see there is still some life and hope for CRXM.

👍️ 1

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Taxus Cardium Pharmaceuticals Group Inc (CE) (CRXM)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CRXM News

FeaturedNorthstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Form REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]

Amended Annual Report (10-k/a)

Annual Report (10-k)

Quarterly Report (10-q)

Amended Current Report Filing (8-k/a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Annual Report (10-k)

Amended Statement of Beneficial Ownership (sc 13d/a)

Statement of Beneficial Ownership (sc 13d)

Initial Statement of Beneficial Ownership (3)

Statement of Ownership (sc 13g)

Initial Statement of Beneficial Ownership (3)

Initial Statement of Beneficial Ownership (3)

CRXM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Taxus Cardium Pharmaceuticals Group Inc (CE) (CRXM) News

Taxus Cardium Pharmaceuticals Group Inc (CE) (CRXM)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CRXM News

FeaturedNorthstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Form REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]

Amended Annual Report (10-k/a)

Annual Report (10-k)

Quarterly Report (10-q)

Amended Current Report Filing (8-k/a)

Current Report Filing (8-k)

Current Report Filing (8-k)

Annual Report (10-k)

Amended Statement of Beneficial Ownership (sc 13d/a)

Statement of Beneficial Ownership (sc 13d)

Initial Statement of Beneficial Ownership (3)

Statement of Ownership (sc 13g)

Initial Statement of Beneficial Ownership (3)

Initial Statement of Beneficial Ownership (3)

CRXM Discussion

Your Recent History

Go Ad-Free